Close

Intercept Pharma (ICPT) Said to Explore Sale Following Interest

February 12, 2016 12:21 PM EST

(Updated - February 12, 2016 12:29 PM EST)

Intercept Pharma (NASDAQ: ICPT) said to explore sale after interest, according to Reuters.

UPDATE - Earlier in February, the U.K.'s Daily Mail said Intercept might put itself up for sale. The list of potential suitors was said to include Shire plc (Nasdaq: SHPG), Gilead Sciences (Nasdaq: GILD), Bristol-Myers Squibb (NYSE: BMY), and Pfizer (NYSE: PFE).

Shares of Intercept are positive Friday, but the stock is still down over 50 percent versus the same period last year.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Mergers and Acquisitions, Rumors, Trader Talk